Olema Pharmaceuticals (NASDAQ:OLMA) Insider Naseem Zojwalla Sells 100,000 Shares of Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) insider Naseem Zojwalla sold 100,000 shares of the firm’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $28.04, for a total value of $2,804,000.00. Following the completion of the sale, the insider owned 53,997 shares of the company’s stock, valued at approximately $1,514,075.88. This represents a 64.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Naseem Zojwalla also recently made the following trade(s):

• On Tuesday, December 23rd, Naseem Zojwalla sold 99,509 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $27.66, for a total transaction of $2,752,418.94.
• On Friday, December 19th, Naseem Zojwalla sold 70,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $28.20, for a total transaction of $1,974,000.00.

Olema Pharmaceuticals Price Performance

Olema Pharmaceuticals stock opened at $27.67 on Wednesday. Olema Pharmaceuticals, Inc. has a 12-month low of $2.86 and a 12-month high of $36.26. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $18.58 and a 200-day moving average price of $10.56. The firm has a market capitalization of $1.90 billion, a PE ratio of -14.80 and a beta of 1.87.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). As a group, equities research analysts forecast that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

Hedge Funds Weigh In On Olema Pharmaceuticals

Large investors have recently bought and sold shares of the business. Susquehanna International Group LLP boosted its position in Olema Pharmaceuticals by 20.6% during the 3rd quarter. Susquehanna International Group LLP now owns 112,277 shares of the company’s stock valued at $1,099,000 after acquiring an additional 19,182 shares in the last quarter. Quarry LP bought a new position in shares of Olema Pharmaceuticals in the 3rd quarter worth $184,000. Paradigm Biocapital Advisors LP lifted its stake in shares of Olema Pharmaceuticals by 0.4% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 6,794,172 shares of the company’s stock worth $66,515,000 after purchasing an additional 30,000 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Olema Pharmaceuticals during the third quarter valued at about $268,000. Finally, Kingdon Capital Management L.L.C. purchased a new position in Olema Pharmaceuticals in the third quarter valued at about $8,361,000. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals News Summary

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Negative Sentiment: Naseem Zojwalla sold 99,509 shares on Dec. 23 at an average $27.66 for ~$2.75M; holding afterward fell to 4,488 shares (a ~95.7% reduction). SEC Form 4 – Zojwalla sale 12/23/2025
• Negative Sentiment: Naseem Zojwalla sold 70,000 shares on Dec. 19 at an average $28.20 for ~$1.97M; his reported direct holding dropped ~40% after that trade. SEC Form 4 – Zojwalla sale 12/19/2025
• Negative Sentiment: Naseem Zojwalla sold 100,000 shares on Dec. 22 at an average $28.04 for ~$2.80M; his combined transactions over the week materially reduced his stake. SEC Form 4 – Zojwalla sale 12/22/2025
• Negative Sentiment: David C. Myles sold 51,000 shares on Dec. 19 at an average $30.46 for ~$1.55M, trimming his position by ~8.5%. SEC Form 4 – Myles sale 12/19/2025
• Negative Sentiment: Director Ian T. Clark sold 264,800 shares on Dec. 19 at an average $29.73 for ~$7.87M — a very large director-level disposal that can amplify market concern. SEC Form 4 – Clark sale 12/19/2025

Analysts Set New Price Targets

Several equities analysts have commented on the company. Citigroup upped their price objective on Olema Pharmaceuticals from $21.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Wednesday, October 8th. Zacks Research raised shares of Olema Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 9th. JPMorgan Chase & Co. boosted their price objective on shares of Olema Pharmaceuticals from $29.00 to $32.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Finally, The Goldman Sachs Group upped their target price on shares of Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $40.50.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.